These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 16510603

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Circulating half-life of PEGylated recombinant methioninase holoenzyme is highly dose dependent on cofactor pyridoxal-5'-phosphate.
    Yang Z, Sun X, Li S, Tan Y, Wang X, Zhang N, Yagi S, Takakura T, Kobayashi Y, Takimoto A, Yoshioka T, Suginaka A, Frenkel EP, Hoffman RM.
    Cancer Res; 2004 Aug 15; 64(16):5775-8. PubMed ID: 15313919
    [Abstract] [Full Text] [Related]

  • 3. In vivo efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5'-phosphate supplementation.
    Sun X, Yang Z, Li S, Tan Y, Zhang N, Wang X, Yagi S, Yoshioka T, Takimoto A, Mitsushima K, Suginaka A, Frenkel EP, Hoffman RM.
    Cancer Res; 2003 Dec 01; 63(23):8377-83. PubMed ID: 14678999
    [Abstract] [Full Text] [Related]

  • 4. PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates.
    Yang Z, Wang J, Lu Q, Xu J, Kobayashi Y, Takakura T, Takimoto A, Yoshioka T, Lian C, Chen C, Zhang D, Zhang Y, Li S, Sun X, Tan Y, Yagi S, Frenkel EP, Hoffman RM.
    Cancer Res; 2004 Sep 15; 64(18):6673-8. PubMed ID: 15374983
    [Abstract] [Full Text] [Related]

  • 5. Development of Recombinant Methioninase for Cancer Treatment.
    Hoffman RM, Tan Y, Li S, Han Q, Yagi S, Takakura T, Takimoto A, Inagaki K, Kudou D.
    Methods Mol Biol; 2019 Sep 15; 1866():107-131. PubMed ID: 30725412
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics, immunogenicity and anticancer efficiency of Aspergillus flavipes L-methioninase.
    El-Sayed AS, Shouman SA, Nassrat HM.
    Enzyme Microb Technol; 2012 Sep 10; 51(4):200-10. PubMed ID: 22883554
    [Abstract] [Full Text] [Related]

  • 7. Polyethylene glycol conjugation of recombinant methioninase for cancer therapy.
    Tan Y, Sun X, Xu M, An Z, Tan X, Han Q, Miljkovic DA, Yang M, Hoffman RM.
    Protein Expr Purif; 1998 Feb 10; 12(1):45-52. PubMed ID: 9473456
    [Abstract] [Full Text] [Related]

  • 8. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
    Bell SJ, Fam CM, Chlipala EA, Carlson SJ, Lee JI, Rosendahl MS, Doherty DH, Cox GN.
    Bioconjug Chem; 2008 Jan 10; 19(1):299-305. PubMed ID: 18020402
    [Abstract] [Full Text] [Related]

  • 9. Overexpression and large-scale production of recombinant L-methionine-alpha-deamino-gamma-mercaptomethane-lyase for novel anticancer therapy.
    Tan Y, Xu M, Tan X, Tan X, Wang X, Saikawa Y, Nagahama T, Sun X, Lenz M, Hoffman RM.
    Protein Expr Purif; 1997 Mar 10; 9(2):233-45. PubMed ID: 9056489
    [Abstract] [Full Text] [Related]

  • 10. Delivery of G3139 using releasable PEG-linkers: impact on pharmacokinetic profile and anti-tumor efficacy.
    Zhao H, Peng P, Longley C, Zhang Y, Borowski V, Mehlig M, Reddy P, Xia J, Borchard G, Lipman J, Benimetskaya L, Stein CA.
    J Control Release; 2007 Jun 04; 119(2):143-52. PubMed ID: 17397960
    [Abstract] [Full Text] [Related]

  • 11. Safety and Toxicity of Recombinant Methioninase and Polyethylene Glycol (PEG) Recombinant Methioninase in Primates.
    Hoffman RM, Yang Z, Tan Y, Han Q, Li S, Yagi S.
    Methods Mol Biol; 2019 Jun 04; 1866():211-229. PubMed ID: 30725418
    [Abstract] [Full Text] [Related]

  • 12. Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation.
    Tsutsumi Y, Kihira T, Tsunoda S, Kamada H, Nakagawa S, Kaneda Y, Kanamori T, Mayumi T.
    J Pharmacol Exp Ther; 1996 Sep 04; 278(3):1006-11. PubMed ID: 8819479
    [Abstract] [Full Text] [Related]

  • 13. Antitumor activity of tumor necrosis factor-alpha conjugated with polyvinylpyrrolidone on solid tumors in mice.
    Kamada H, Tsutsumi Y, Yamamoto Y, Kihira T, Kaneda Y, Mu Y, Kodaira H, Tsunoda SI, Nakagawa S, Mayumi T.
    Cancer Res; 2000 Nov 15; 60(22):6416-20. PubMed ID: 11103807
    [Abstract] [Full Text] [Related]

  • 14. Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency.
    Yoshioka Y, Tsutsumi Y, Ikemizu S, Yamamoto Y, Shibata H, Nishibata T, Mukai Y, Okamoto T, Taniai M, Kawamura M, Abe Y, Nakagawa S, Nagata S, Yamagata Y, Mayumi T.
    Biochem Biophys Res Commun; 2004 Mar 19; 315(4):808-14. PubMed ID: 14985084
    [Abstract] [Full Text] [Related]

  • 15. Broad selective efficacy of rMETase and PEG-rMETase on cancer cells in vitro.
    Tan Y, Xu M, Hoffman RM.
    Anticancer Res; 2010 Mar 19; 30(3):793-8. PubMed ID: 20392998
    [Abstract] [Full Text] [Related]

  • 16. Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-alpha: a novel polymer-conjugation technique with a reversible amino-protective reagent.
    Tsunoda S, Ishikawa T, Yamamoto Y, Kamada H, Koizumi K, Matsui J, Tsutsumi Y, Hirano T, Mayumi T.
    J Pharmacol Exp Ther; 1999 Jul 19; 290(1):368-72. PubMed ID: 10381801
    [Abstract] [Full Text] [Related]

  • 17. Co-immobilization of PEGylated Aspergillus flavipes L-methioninase with glutamate dehydrogenase: a novel catalytically stable anticancer consortium.
    El-Sayed AS, Ibrahim H, Sitohy MZ.
    Enzyme Microb Technol; 2014 Jan 10; 54():59-69. PubMed ID: 24267569
    [Abstract] [Full Text] [Related]

  • 18. Pharmacologic properties of polyethylene glycol-modified Bacillus thiaminolyticus thiaminase I enzyme.
    Liu S, Bae Y, Leggas M, Daily A, Bhatnagar S, Miriyala S, St Clair DK, Moscow JA.
    J Pharmacol Exp Ther; 2012 Jun 10; 341(3):775-83. PubMed ID: 22431205
    [Abstract] [Full Text] [Related]

  • 19. Effect of divalent polyethylene glycol units, conjugated on human granulocyte colony-stimulating factor, on biological activities in vitro and in vivo.
    Yamasaki M, Asano M, Yokoo Y, Okabe M.
    Drugs Exp Clin Res; 1998 Jun 10; 24(4):191-6. PubMed ID: 10051965
    [Abstract] [Full Text] [Related]

  • 20. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
    Chow TH, Lin YY, Hwang JJ, Wang HE, Tseng YL, Wang SJ, Liu RS, Lin WJ, Yang CS, Ting G.
    Anticancer Res; 2009 Jun 10; 29(6):2111-20. PubMed ID: 19528471
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.